favipiravir / Generic mfg. - LARVOL DELTA

Re-evaluating a single-arm trial of favipiravir for severe fever with thrombocytopenia syndrome in Japan: A proposal to use real-world data as external controls. (PubMed, PLoS Negl Trop Dis) - No abstract available

Journal • Real-world evidence • Hematological Disorders • Thrombocytopenia

Carboxylesterase Factors Influencing the Therapeutic Activity of Common Antiviral Medications Used for SARS-CoV-2 Infection. (PubMed, Pharmaceutics) - "Several small-molecule antiviral drugs, including molnupiravir, favipiravir, remdesivir, and nirmatrelvir have been shown to inhibit SARS-CoV-2 replication and are approved for treating SARS-CoV-2 infections. In this review, we examine how CES-related cellular and genetic factors influence the therapeutic activities of these widely used COVID-19 medications. This article highlights implications for improving product design, targeted inhibition, and personalized medicine by exploring genetic variations and their impact on drug metabolism and efficacy."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Comparative insights to microwave and ultrasound as extraction tools for on-spot protein denaturation and HPLC-UV determination of favipiravir in human plasma: Application to real sample and storage stability. (PubMed, J Chromatogr A) - "The developed methods exhibited excellent analytical performance, increased throughput, reduced volumes of sample (10 μL) and organic solvents (210 μL), and negligible waste. Thus, it can be adopted for routine work in pharmacokinetics and clinical trial studies."

Journal

A cap-dependent endonuclease inhibitor acts as a potent antiviral agent against La Crosse virus infection. (PubMed, Antimicrob Agents Chemother) - "CAPCA-1 exhibited 50% effective concentration values below 1 µM in neuronal and non-neuronal cells, demonstrating a higher in vitro activity than the nucleoside analogs, ribavirin and favipiravir. Notably, using a lethal infection model in mice, CAPCA-1 treatment reduced viral loads in the brain and extended the survival rate of LACV-infected mice. These findings highlight the potential of CEN inhibitors as treatment options for La Crosse encephalitis."

Journal • CNS Disorders • Infectious Disease

Organ-specific effects of curcumin on favipiravir-induced oxidative stress: renal benefit and hepatic risk. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "FAV causes sub-clinical liver and kidney injury that is not accompanied by lipid peroxidation or enzyme leakage at 14 days. CUR exerts dual actions-mitigating renal apoptosis yet amplifying hepatic lipid peroxidation-highlighting an organ-specific risk-benefit ratio that should be weighed before empirical antioxidant supplementation during FAV therapy."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Renal Disease • Respiratory Diseases • IL6 • TNFA

Development and validation of a RP-HPLC method for simultaneous determination of five COVID-19 antiviral drugs in pharmaceutical formulations. (PubMed, Sci Rep) - "A rapid, sensitive, and selective reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the simultaneous determination of five COVID-19 antiviral drugs: favipiravir, molnupiravir, nirmatrelvir, remdesivir, and ritonavir. Comprehensive greenness and practicality evaluations using five assessment tools yielded favorable scores: AGREE (0.70), AGREEprep (0.59), MoGAPI (70%), BAGI (82.5), and CACI (79), indicating good environmental performance and excellent practical applicability for routine pharmaceutical quality control analysis. The multi-tool assessment confirmed the method's environmental friendliness through strategic solvent selection and minimal sample preparation requirements, while demonstrating superior practical implementation characteristics including cost-effectiveness and accessibility in standard analytical laboratories."

Journal • Infectious Disease • Novel Coronavirus Disease

Pregnancy outcomes following maternal exposure to favipiravir: A Terafar case series. (PubMed, Neurotoxicol Teratol) - "Our study does not indicate a major teratogenic signal regarding favipiravir exposure in pregnancy, though the higher elective termination rate suggests increased risk perception. While study limitations prevent definitive conclusions, our findings may be of value to clinicians in counseling pregnant women regarding favipiravir exposure."

Journal • Atopic Dermatitis • Dermatology • Developmental Disorders • Immunology • Nephrology • Respiratory Diseases • Vitiligo

Magnetic orange leaf biochar for favipiravir removal from wastewater. (PubMed, Sci Rep) - "Characterization of spent adsorbent confirmed preservation of magnetic properties (52 wt% Fe retention) and structural integrity. These findings establish MBC-OL as a sustainable, high-capacity adsorbent for pharmaceutical wastewater treatment, with significant potential for agricultural waste valorization in circular economy applications."

Journal

ARSYNAL-FC: Assessing Antiviral Treatments in Early Symptomatic RSV (clinicaltrials.gov) - P2 | N=1000 | Recruiting | Sponsor: University of Oxford | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Multilinear regression analysis of antiviral medications with topological indices. (PubMed, J Mol Graph Model) - "In this research, we investigate degree-based topological indices (TIs) that serve as molecular descriptors for the QSPR analysis of antiviral medications such as Favipiravir, Sertraline, Chloroquine, Ribavirin, Bepridil, Clomifene, Galidesivir, Nilotinib, and Brincidofovir, which affect the interactions between viruses and human proteins. We examine both linear and multilinear QSPR models to analyze the connections between different physical and chemical properties including molecular polarizability (MP), Log P, molecular refractivity (MR), and molecular weight (MW) and the numerical values associated with these drugs. Our results indicate a strong correlation between the topological indices of these antiviral medications and their physical and chemical characteristics."

Journal

Case Report: Successful treatment of severe fever with thrombocytopenia syndrome associated with hemophagocytic lymphohistiocytosis by preemptively using favipiravir and methylprednisolone. (PubMed, Front Med (Lausanne)) - "Excitingly, the patient was recovered after 10 days treatment. Early recognition of SFTS complicated with HLH is particularly important, and the preemptive application of favipiravir may improve the prognosis of these patients."

Journal • Fatigue • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Rare Diseases • Thrombocytopenia

Structure-based identification of dual targeting lead inhibitor to Marburg virus glycoprotein and Chandipura virus nucleoprotein: Insights from molecular docking, dynamics and binding free energy analyses. (PubMed, Biochem Biophys Res Commun) - "Licorice compounds with satisfactory pharmacokinetics such as drug likeness and ADMET, were docked against these targets, and comparison was made with the docking results of the reference antiviral drug, favipiravir and the target VP35 by using their binding affinities...Binding free energy calculations, conducted using MM/GBSA and MM/PBSA, also estimated ΔG values of -679.65 kcal/mol and -92.30 kcal/mol for apigenin-GP and apigenin-NP complexes. This in silico model highlights apigenin from Glycyrrhiza glabra as a potential dual targeting antiviral therapeutic against both CHPV and MARV, and finds significant applications in further in vitro and in vivo validation."

Journal • CNS Disorders • Hematological Disorders

Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial. (PubMed, Antimicrob Agents Chemother) - P2 | "Favipiravir was well tolerated with few AEs but was associated with increased variant frequency, including C-to-U mutations. Community administration of favipiravir for mild COVID-19 was not associated with clinical benefits or safety concerns but was associated with SARS-CoV-2 mutagenicity.CLINICAL TRIALSThis study is registered with ISRCTN as 31062548 and with EU-CTR as 2020-001904-41."

Journal • P3 data • Critical care • Gout • Hepatology • Infectious Disease • Inflammatory Arthritis • Novel Coronavirus Disease • Respiratory Diseases • Rheumatology

Efficacy and safety of remdesivir and favipiravir in COVID-19 patients - A systematic review and meta-analysis. (PubMed, J Family Med Prim Care) - "Worsening of comorbidities (OR 0.94; 95% CI 0.81-1.08; I2= 0%), Ferritin level measured (OR-19.80 95% CI -56.51-16.92; I2 = 0 %) and Transferred to ICU/ Mechanical Ventilation (OR 0.85 95% CI 0.25 -2.91; I2 = 52 %) were observed in both the anti-viral. This meta-analysis found mixed efficacy for Remdesivir and negative outcomes for Favipiravir."

Journal • Retrospective data • Review • Infectious Disease • Novel Coronavirus Disease

HPLC-Based Quantitative Assessment of Antiviral Agents in Artificial Saliva. (PubMed, Drug Dev Ind Pharm) - "A novel high-performance liquid chromatographic (HPLC) method for simultaneous analysis of three selected antivirals: Tenofovir Disoproxil Fumarate (TDF), Favipiravir (FAV), Ritonavir (RIT) and internal standard as another antiviral (emtricitabine) in artificial saliva was optimized and validated, including sample preparation using new extraction procedure. The method has been found according to ICH guidelines specific, accurate (recovery, 93.003% - 103.357%), sensitive (LOD and LOQ were values found as 0.03 and 0.1 µg/mL, respectively), and precise (RSD; 0.412% - 3.175%). A validated HPLC method was developed for the precise determination of different antiviral agents in artificial saliva."

Journal

Electrocardiographic alterations in patients treated for acute Lassa Fever: Description of results from a phase II clinical trial in Nigeria. (PubMed, J Infect Public Health) - "ECG alterations observed in both treatment arms are compatible with direct cardiac effects of the LASV. The combination of new onset of chest pain combined with the evolution of ECG findings over time are suggestive for the occurrence of perimyocarditis in a subset of patients."

Journal • P2 data • Cardiovascular • CNS Disorders • Hematological Disorders • Infectious Disease • Pain

In-hospital mortality outcomes of favipiravir in patients with moderate to severe COVID-19 infection: An emulated target trial using real-world data from the largest field hospital in Thailand. (PubMed, PLoS One) - "Our emulated target trial suggests favipiravir, especially with dexamethasone, offers a modest survival benefit in moderate to severe COVID-19, particularly in hypoxic patients. It supports favipiravir as a practical antiviral in settings where other antivirals are not available. Further randomized controlled studies are needed to confirm its role, alongside standard corticosteroid therapy."

Journal • Observational data • Real-world evidence • Infectious Disease • Novel Coronavirus Disease

Evaluating the Potential Adverse Effects of Favipiravir on Biochemical, Histopathological, and Spermatological Parameters in Male Rats' Testicular Tissue. (PubMed, J Biochem Mol Toxicol) - "Favipiravir administration decreases the expression of genes that induce sperm capacitation and acrosome reaction and decreases sperm quality by causing changes in testicular histoarchitecture. Study results reveal that favipiravir treatment negatively affects testes and semen quality."

Adverse events • IO biomarker • Journal • Preclinical • Inflammation • BCL2 • CASP3 • PI3K

Synthesis and anti-SARS-CoV-2 potential of novel coumarin hybrids: a combined wet/dry lab approach targeting MPro, Nsp15 and spike protein. (PubMed, RSC Adv) - "Among all, compounds 14b and 14c expressed excellent potency against their respective targets with corresponding binding affinities of -9.5 kcal mol-1 (6VWW), -9.2 kcal mol-1 (6Y84), and -8.6 (6WPT) kcal mol-1, even better than all standards i.e., chloroquine, lopinavir, remdesivir, favipiravir, and nirmatrelvir. The stability of the potent compounds (14b and 14c) was further supported by a 100 ns MD simulation, emphasizing their potent and stable interactions with the main protease, endoribonuclease, and spike protein. The current study highlights the coumarin-based conjugates 14(a-h) and 17(a-h) as attractive and promising candidates for future pharmacological interventions against SARS-CoV-2."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Evolving therapeutic strategies for severe fever with thrombocytopenia syndrome: from past to future. (PubMed, Ther Adv Infect Dis) - "Favipiravir has advantages over ribavirin in terms of viral clearance and prognosis. Conventional immunomodulators like interferon, intravenous immunoglobulin, and glucocorticoids have limited effects and may even worsen conditions, whereas novel immunomodulators such as tocilizumab and ruxolitinib have shown potential for improving prognosis...Additionally, plasma exchange, calcium channel blockers, and arginine can improve laboratory values and expedite viral clearance. In the future, screening Food and Drug Administration-approved drugs and conducting multiomics analyses may lead to the discovery of new effective therapeutic options."

Journal • Review • Hematological Disorders • Leukopenia • Thrombocytopenia

Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis. (PubMed, BMJ) - "Nirmatrelvir-ritonavir and remdesivir probably reduce admission to hospital, and systemic corticosteroids and molnupiravir may reduce admission to hospital. Several medications including systemic corticosteroids and molnupiravir probably reduce time to symptom resolution."

Clinical • Journal • Retrospective data • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Green synthesis of structural analogs of favipiravir. (PubMed, RSC Adv) - "In reactions with arylglyoxals 1a, 1d, 1h, and 1i, temperatures exceeding 80 °C produced a mixture of two regioisomeric pyrazine derivatives with significant efficiency. This method is highly desirable due to its short reaction time, simple purification of products, and the use of water as an eco-friendly solvent."

Journal

Preparation, and ex vivo and in vivo Characterization of Favipiravir-Loaded Aspasomes and Niosomes for Nose-to-Brain Administration. (PubMed, Int J Nanomedicine) - "The in vitro-in vivo correlation study showed good correlation between the in vitro and the in vivo pharmacokinetic data. FAV-ASP8 for nose-to-brain delivery system could be a promising formulation to improve FAV bioavailability compared to FAV-NIO9."

Journal • Preclinical

Repositioning Antivirals Against COVID-19: Synthetic Pathways, Mechanisms, and Therapeutic Insights. (PubMed, Microb Pathog) - "Remdesivir, Favipiravir, Hydroxychloroquine, and Chloroquine have been the focus of rigorous clinical trials to determine their therapeutic potential against SARS-CoV-2. It also underscores the vital function of chemistry in addressing global health emergencies and highlights how innovative drug design and repurposing can provide rapid responses to emerging infectious diseases. This fusion of chemistry and virology not only advances our understanding of drug action but also paves the way for the discovery of new therapeutic agents crucial in future pandemics."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Predictors of Mortality Among Hospitalized Patients With Covid-19: Retrospective Analysis (ATS 2025) - "Data on use of antiviral drugs (favipiravir or remdesivir) and systemic corticosteroids (dexamethasone, methylprednisolone) was also collected. Serial waves of COVID-19, emergence of mutant strains, limitations in availability of antiviral drugs poses additional threat to the already strained health systems across the globe and in particular the developing and underdeveloped economies. Presence of comorbidities and biomarker cut offs could alert the physicians to more aggressive damage control especially in health systems of developing countries which are already over burdened due to lack of resources."

Retrospective data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IL6